Delivery Order HHSF223201510001I-HHSF22301006T
Award Date
9/11/17
Potential Completion Date
4/15/21
Potential Value
$1.1M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Lovelace Biomedical Research Institute
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Albuquerque, NM 87108, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to conduct in vitro evaluation of the toxic profiles of tobacco additives in a systematic tiered approach. The contract has a ceiling value of $1,552,162.00 and an ultimate completion date of July 14, 2018. It was issued under the FDA's "In Vivo Toxicology of Tobacco...
This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
This is a $897,471 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. LBERI, a non-profit contract research organization, will provide preclinical research services to support the...
This is a firm-fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $1,405,301.00 contract is for in vitro evaluation of the toxic profiles of tobacco additives using a systematic tiered approach. It is part of the larger "In Vivo Toxicology of Tobacco 2015-2020" indefinite delivery, indefinite quantity (IDIQ) contract vehicle....
This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for $679,680.00. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Under this task order, LBERI will conduct an assessment of tobacco products and tobacco product constituents' genetic toxicology using in vitro assays to compare the...
This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
This is a $1,251,731.00 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract, which has no set-aside designation, is part of Task Order 2 under a larger contract vehicle and is focused on examining the influence of synthetic cooling agents on cigarette sensory and subjective effects, as well as use behavior. Lovelace Biomedical Research...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The contract has a potential value of $1,835,595.00 and is for a study to investigate the subjective effects and nicotine pharmacokinetics of mentholated smokeless tobacco products in current users. The contract is part of a larger Tobacco Products Pharmacology Study indefinite...
The Department of Health and Human Services Food and Drug Administration awarded a $36,286,201 firm-fixed-price definitive contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to conduct a study on the toxicity of e-cigarette aerosol in in vivo nonclinical models. The contract does not have a set-aside designation and is scheduled for completion by February 28, 2025. Vamco, LLC, a small disadvantaged business, was awarded a subcontract to...